Data / Drug companies / Hainan Poly Pharm. Co., Ltd.
Hainan Poly Pharm. Co., Ltd.: 30 products in the FDA NDC directory, labeler code 14335
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
Hainan Poly Pharm. Co., Ltd. (labeler code 14335) lists 30 products in the FDA National Drug Code Directory, covering 7 finished drugs by generic name. By type: 15 bulk ingredients, 15 prescription drugs. Its main marketing category is generic drugs (ANDA). The newest product started marketing on May 14, 2026.
The request: Watch Hainan Poly Pharm. Co., Ltd. (FDA labeler code 14335): each new product listing and each discontinued product. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 14335
- Products in commercial distribution
- 30
- Packages
- 32
- Finished drugs by generic name
- 7
- Prescription products
- 15
- Over the counter products
- 0
- Controlled substance products
- Schedule V 1
- Flagged as original packager
- 15 of 15 products that carry the flag
- Started marketing in the last 12 months
- 3
- Earliest marketing start
- December 10, 2021
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| Generic drugs (ANDA) | 15 | 50% |
| Bulk ingredients for compounding | 13 | 43.3% |
| Bulk ingredients | 2 | 6.7% |
Products by type
| Type | Products | Share |
|---|---|---|
| Bulk ingredients | 15 | 50% |
| Prescription drugs | 15 | 50% |
Drugs it lists
Finished drugs by generic name, with how many companies list each.
| Drug | Products | Companies listing it |
|---|---|---|
| Sodium nitroprusside | 4 | 14 |
| Phenylephrine hydrochloride | 3 | 77 |
| Cyclophosphamide for injection | 3 | 3 |
| Levoleucovorin injection | 2 | 2 |
| Brivaracetam | 1 | 17 |
| Daptomycin | 1 | 25 |
| Voriconazole | 1 | 34 |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Powder | 15 | 50% |
| Injection, solution | 6 | 20% |
| Injection | 4 | 13.3% |
| Injection, powder, for solution | 3 | 10% |
| Injection, solution, concentrate | 1 | 3.3% |
| Injection, powder, lyophilized, for suspension | 1 | 3.3% |
Pharmacologic classes
FDA established pharmacologic classes of its products.
| Class | Products |
|---|---|
| Vasodilator | 4 |
| alpha-1 Adrenergic Agonist | 3 |
| Folate Analog | 2 |
| Lipopeptide Antibacterial | 1 |
| Azole Antifungal | 1 |
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Anhui poly pharm. co., ltd. | 14335-801 | Powder | Bulk ingredients for compounding | May 14, 2026 |
| Brivaracetam | 14335-420 | Injection | Generic drugs (ANDA) | February 21, 2026 |
| Voriconazole | 14335-730 | Injection, solution | Generic drugs (ANDA) | November 20, 2025 |
| Ioversol | 14335-590 | Powder | Bulk ingredients for compounding | July 30, 2025 |
| Semaglutide | 14335-790 | Powder | Bulk ingredients for compounding | February 28, 2025 |
| Cyclophosphamide | 14335-472 | Injection, powder, for solution | Generic drugs (ANDA) | January 3, 2025 |
| Cyclophosphamide | 14335-471 | Injection, powder, for solution | Generic drugs (ANDA) | January 3, 2025 |
| Cyclophosphamide | 14335-470 | Injection, powder, for solution | Generic drugs (ANDA) | January 3, 2025 |
| Sodium nitroprusside | 14335-131 | Injection, solution, concentrate | Generic drugs (ANDA) | August 13, 2024 |
| Allopurinol | 14335-530 | Powder | Bulk ingredients for compounding | July 29, 2024 |
| Sodium nitroprusside | 14335-130 | Powder | Bulk ingredients for compounding | May 31, 2024 |
| Phenylephrine Hydrochloride | 14335-442 | Injection | Generic drugs (ANDA) | March 19, 2024 |
| Phenylephrine Hydrochloride | 14335-441 | Injection | Generic drugs (ANDA) | March 19, 2024 |
| Phenylephrine Hydrochloride | 14335-440 | Injection | Generic drugs (ANDA) | March 19, 2024 |
| Crisaborole | 14335-700 | Powder | Bulk ingredients for compounding | November 30, 2023 |
| Gadobutrol | 14335-580 | Powder | Bulk ingredients for compounding | November 30, 2023 |
| Daptomycin | 14335-120 | Injection, powder, lyophilized, for suspension | Generic drugs (ANDA) | November 14, 2023 |
| Tecovirimat monohydrate | 14335-680 | Powder | Bulk ingredients for compounding | September 20, 2023 |
| Voriconazole | 14335-450 | Powder | Bulk ingredients for compounding | September 1, 2023 |
| Apremilast | 14335-433 | Powder | Bulk ingredients for compounding | August 15, 2023 |
| Levoleucovorin calcium | 14335-341 | Injection, solution | Generic drugs (ANDA) | May 31, 2023 |
| Levoleucovorin calcium | 14335-340 | Injection, solution | Generic drugs (ANDA) | May 31, 2023 |
| Gadoteridol | 14335-390 | Powder | Bulk ingredients for compounding | February 9, 2023 |
| Sodium Nitroprusside | 14335-134 | Injection, solution | Generic drugs (ANDA) | December 31, 2022 |
| Sodium Nitroprusside | 14335-133 | Injection, solution | Generic drugs (ANDA) | December 31, 2022 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.